Page 180

Andrew I. Schoenholtz, Director of Law and Policy Studies, Georgetown University

Douglas Shenson, M.D. M.P.H., Director, Human Rights Clinic, Montefiore Medical Center, North Central Bronx Hospital

8:45 a.m.–10:15 a.m.

Can tuberculin skin testing be conducted for immigrants to the United States in their country of origin?

Can a B3 category be created for individuals with a positive tuberculin skin test and people in this category be processed much as category B1 and B2 immigrants are processed now?

Can the health screening requirements differ on the basis of country of origin?

Is the estimated prevalence of infection in other countries a suitable criterion for deciding who should be tuberculin tested prior to arrival?

Should immigrants from Mexico be tuberculin skin tested prior to immigration, since individuals born in Mexico account for the greatest number of foreign-born cases, even though the official estimates of the prevalence of infection is not above the global median?

10:15 a.m.–10:30 a.m.

Break

10:30 a.m.–12:30 p.m.

Can the completion of tuberculosis screening for immigrants with Class B waivers be tied to the right to permanent residence in the United States?

Should the completion of tuberculosis screening for immigrants with Class B waivers be tied to the right to permanent residence in the United States?

Should the completion of treatment for latent infection be legally mandated for individuals with the highest risk for developing tuberculosis?



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement